logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hao-Rui Shen

南京医科大学
H指数:10
被引数:352

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

Penpulimab联合利妥昔单抗、大剂量甲氨蝶呤和阿糖胞苷（Pen-RMA）治疗新诊断的原发性中枢神经系统淋巴瘤（PCNSL）：一项II期临床试验

Blood Cancer Journal
IF11.6
2026-02-110
OA
Hao-Rui Shen; Jia-Zhu Wu; Hua Yin; Kai-Xin Du; Luthuli Sibusiso; Yi-Fan Wu; Wei Hua; Yue Li; Yi-Lin Kong; Xin-Yu Zhang; Rui Gao; Jian-Yong Li; Li Wang; Jin-Hua Liang; Wei Xu
Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Penpulimab联合来那度胺和r-gemox方案 (R2-GemOx-PD1i) 治疗复发或难治性弥漫性大b细胞淋巴瘤: 一项多中心，单臂，2期试验

BMC Medicine
IF8.3
2026-02-090
OAAI
Jin-Hua Liang; Tong-Yao Xing; Wei-Ying Gu; Hua Yin; Qing-Shu Zeng; Kai-Xin Du; Luthuli Sibusiso; Jia-Zhu Wu; Yue Li; Fei Wang; Rui Gao; Jian-Yong Li; Hao-Rui Shen; Li Wang; Wei Xu
Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study

基于ctDNA的微小残留病灶检测在新诊断的外周T细胞淋巴瘤中的临床意义：一项单中心队列研究

Cell Communication and Signaling
IF8.9
2025-10-170
OAAI
Jin-Hua Liang; Wei Hua; Hua Yin; Yue Li; Xin-Yi Zhang; Jun-Heng Liang; Liu-Qing Zhu; Rui Gao; Chen-Xuan Wang; Yang Shao; Bi-Hui Pan; Xin-Yu Zhang; Jia-Zhu Wu; Qiu-Xiang Ou; Jian-Yong Li; Hao-Rui Shen; Li Wang; Wei Xu
The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma

第一类PTPN2/1抑制剂Abbv-CLS-484破坏线粒体更新并阻断Tfrc介导的PINK1-Prkn依赖性线粒体自噬，从而在ALK阳性间变性大细胞淋巴瘤中发挥抗肿瘤活性。

BLOOD
IF23.1
2024-11-050
PRE
Liang, Jinhua; Wang, Weiting; Duan, Ziwen; Xing, Tong-Yao; Shen, Hao-Rui; Yin, Hua; Wang, Li; Li, Jianyong; Wei, Xu
A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

一项前瞻性、开放标签、多中心、随机对照研究，比较泊洛妥珠单抗、利妥昔单抗、环磷酰胺、多柔比星和泼尼松联合奥雷巴替尼/西地酰胺/维奈克拉/来那度胺/本妥昔单抗（Pola-RCHP-X）与RCHOP-X和Pola-RCHP在初治弥漫大B细胞淋巴瘤患者中的疗效和安全性。

BLOOD
IF23.1
2024-11-050
PRE
Liang, Jinhua; Wang, Li; Shen, Haorui; Yin, Hua; Wu, Jiazhu; Li, Yue; Pan, Bihui; Zhang, Xinyu; Kong, Yilin; Li, Jianyong; Wei, Xu

研究方向

暂未获取到该数据
J
Jianyong Li
H 指数:54论文数:1,071被引数:1.5万
J
Jin‐Hua Liang
H 指数:21论文数:205被引数:1,613
W
Wei Xu
H 指数:42论文数:662被引数:7,739
J
Jia‐Zhu Wu
H 指数:17论文数:159被引数:1,086
H 指数:0论文数:88被引数:255
L
Li Wang
H 指数:70论文数:1,168被引数:3.0万
K
Kai‐Xin Du
H 指数:6论文数:25被引数:120
Y
Yue Li
H 指数:18论文数:82被引数:946
R
Rui Gao
H 指数:31论文数:177被引数:2,832
W
Wei‐Ting Wang
H 指数:27论文数:350被引数:3,307